Results 91 to 100 of about 1,854,852 (401)

Prospective multicenter randomized patient recruitment and sample collection to enable future measurements of sputum biomarkers of inflammation in an observational study of cystic fibrosis

BMC Medical Research Methodology, 2019
Background Biomarkers of inflammation predictive of cystic fibrosis (CF) disease outcomes would increase the power of clinical trials and contribute to better personalization of clinical assessments.
Theodore G. Liou, Frederick R. Adler, Natalia Argel, Fadi Asfour, Perry S. Brown, Barbara A. Chatfield, Cori L. Daines, Dixie Durham, Jessica A. Francis, Barbara Glover, Theresa Heynekamp, John R. Hoidal, Judy L. Jensen, Ruth Keogh, Carol M. Kopecky, Noah Lechtzin, Yanping Li, Jerimiah Lysinger, Osmara Molina, Craig Nakamura, Kristyn A. Packer, Katie R. Poch, Alexandra L. Quittner, Peggy Radford, Abby J. Redway, Scott D. Sagel, Shawna Sprandel, Jennifer L. Taylor-Cousar, Jane B. Vroom, Ryan Yoshikawa, John P. Clancy, J. Stuart Elborn, Kenneth N. Olivier, David R. Cox   +33 more
doaj   +1 more source

Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials [PDF]

, 2013
Rationale Clinical trial design in interstitial lung diseases (ILDs) has been hampered by lack of consensus on appropriate outcome measures for reliably assessing treatment response.
Antoniou, K, Baughman, RP, Brown, KK, Castelino, FV, Christmann, RB, Christopher-Stine, L, Collard, HR, Cottin, V, Danoff, S, Dellaripa, PF, Denton, CP, Distler, O, Fischer, A, Flaherty, KR, Frankel, S, Highland, KB, Hummers, L, Huscher, D, Khanna, D, Kim, DS, Kowal-Bielecka, OM, LeSage, D, Lynch, DA, Matteson, EL, Merkel, PA, Miller, FW, Mittoo, S, Oddis, CV, Phillips, K, Pittrow, D, Proudman, SM, Richeldi, L, Ryu, JH, Saketkoo, LA, Sandorfi, N, Sarver, C, Seibold, JR, Shah, AA, Strand, V, Swigris, J, Wells, AU   +40 more
core   +1 more source

LOXHD1 and RHOB Expression by Monocytes Predicts Progressive Systemic Sclerosis associated Interstitial Lung Disease

Arthritis Care &Research, Accepted Article.
Objective A leading cause of death among scleroderma (SSc) patients, interstitial lung disease (ILD) remains challenging to prognosticate. The discovery of biomarkers that accurately determine which patients would benefit from close monitoring and aggressive therapy would be an essential clinical tool.
Cristina M Padilla, Robert Lafyatis, Kevin F Gibson, Christina Morse, Eleanor Valenzi, Xiaoping Chen, Xiaoyun Li, Yanwu Zhao, Yongseok Park, Dana Ascherman, Jonathan Minden, Robyn Domsic, Yingze Zhang, Daniel J Kass   +13 more
wiley   +1 more source

Regulatory T cell enhancement in adults with cystic fibrosis receiving Elexacaftor/Tezacaftor/Ivacaftor therapy

Frontiers in Immunology, 2023
IntroductionCystic fibrosis (CF), especially CF lung disease, is characterized by chronic infection, immune dysfunction including impairment of regulatory T cells (Tregs) and an exaggerated inflammatory response.
Dirk Westhölter, Jonas Raspe, Hendrik Uebner, Johannes Pipping, Mona Schmitz, Svenja Straßburg, Sivagurunathan Sutharsan, Matthias Welsner, Christian Taube, Sebastian Reuter   +9 more
doaj   +1 more source

Pulmonary Fibrosis in Children [PDF]

Journal of Clinical Medicine, 2019
Pulmonary fibrosis (PF) is a very rare condition in children, which may be observed in specific forms of interstitial lung disease. None of the clinical, radiological, or histological descriptions used for PF diagnosis in adult patients, especially in situations of idiopathic PF, can apply to pediatric situations.
Nathan, Nadia, Sileo, Chiara, Thouvenin, Guillaume, Berdah, Laura, Delestrain, Céline, Manali, Effrosyne, Papiris, Spyros, Léger, Pierre-Louis, Ducou Le Pointe, Hubert, Coulomb L'Hermine, Aurore, Clement, Annick   +10 more
openaire   +3 more sources

Heterogeneity of Rheumatoid Arthritis–Associated Interstitial Lung Disease by Longitudinal Forced Vital Capacity Trajectory and Associations With Disease Outcomes

Arthritis Care &Research, EarlyView.
Objective We aimed to identify unique disease trajectories within rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) based on longitudinal forced vital capacity (FVC) values and their associated clinical outcomes. Methods We performed a cohort study of RA‐ILD within the Veterans Health Administration from 1999 to 2021.
Bryant R. England, Yangyuna Yang, Punyasha Roul, Tate M. Johnson, Scott M. Matson, Grant W. Cannon, Brian C. Sauer, Jeffrey R. Curtis, Joshua F. Baker, Ted R. Mikuls   +9 more
wiley   +1 more source

NR2F2 alleviates pulmonary fibrosis by inhibition of epithelial cell senescence

Respiratory Research
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fatal, and aging-associated interstitial lung disease with a poor prognosis and limited treatment options, while the pathogenesis remains elusive.
Ruyan Wan, Siqi Long, Shuaichen Ma, Peishuo Yan, Zhongzheng Li, Kai Xu, Hui Lian, Wenwen Li, Yudi Duan, Miaomiao Zhu, Lan Wang, Guoying Yu   +11 more
doaj   +1 more source

Signaling pathways of liver regeneration: Biological mechanisms and implications

iScience
Summary: The liver possesses a unique regenerative ability to restore its original mass, in this regard, partial hepatectomy (PHx) and partial liver transplantation (PLTx) can be executed smoothly and safely, which has important implications for the ...
Chunyan Zhang, Caifang Sun, Yabin Zhao, Bingyu Ye, GuoYing Yu   +4 more
doaj   +1 more source

Senescence of Alveolar Type 2 Cells Drives Progressive Pulmonary Fibrosis.

American Journal of Respiratory and Critical Care Medicine, 2020
RATIONALE Idiopathic pulmonary fibrosis (IPF) is an insidious and fatal interstitial lung disease associated with declining pulmonary function. Accelerated aging, loss of epithelial progenitor cell function and/or numbers and cellular senescence are ...
C. Yao, Xiangrong Guan, G. Carraro, T. Parimon, Xue Liu, Guanling Huang, Apoorva Mulay, H. Soukiasian, G. David, S. Weigt, J. Belperio, Peter Chen, D. Jiang, P. Noble, B. Stripp   +14 more
semanticscholar   +1 more source

Rethinking Strategies for a Pharmaceutical Approach to Pain Related to Connective Tissue–Related Raynaud Phenomenon in the United States

Arthritis Care &Research, EarlyView.
Objective There are no US Food and Drug Administration–approved therapies for Raynaud phenomenon (RP) in the United States. Clinical trials have been challenged by study design. Important advances in RP patient‐reported outcome measures and mechanistic quantification allow RP‐related pain characterization.
Tracy M. Frech, Charles G. Frech, W. David Merryman, Andrew Sternlicht, Justin Baba   +4 more
wiley   +1 more source